Glycogen storage disease explained

Glycogen storage disease
Synonyms:Glycogenosis; dextrinosis
Specialty:neuromuscular medicine
hepatology; medical genetics
Symptoms:Biopsy shows either abnormal accumulation or deficit of glycogen
Causes:Genetic

A glycogen storage disease (GSD, also glycogenosis and dextrinosis) is a metabolic disorder caused by a deficiency of an enzyme or transport protein affecting glycogen synthesis, glycogen breakdown, or glucose breakdown, typically in muscles and/or liver cells.[1]

GSD has two classes of cause: genetic and environmental. Genetic GSD is caused by any inborn error of carbohydrate metabolism (genetically defective enzymes or transport proteins) involved in these processes. In livestock, environmental GSD is caused by intoxication with the alkaloid castanospermine.[2]

However, not every inborn error of carbohydrate metabolism has been assigned a GSD number, even if it is known to affect the muscles or liver. For example, phosphoglycerate kinase deficiency (gene PGK1) has a myopathic form.

Also, Fanconi-Bickel syndrome (gene SLC2A2) and Danon disease (gene LAMP2) were declassed as GSDs due to being defects of transport proteins rather than enzymes; however, GSD-1 subtypes b, c, and d are due to defects of transport proteins (genes SLC37A4, SLC17A3) yet are still considered GSDs.

Phosphoglucomutase deficiency (gene PGM1) was declassed as a GSD due to it also affecting the formation of N-glycans; however, as it affects both glycogenolysis and glycosylation, it has been suggested that it should re-designated as GSD-XIV.[3]

(See inborn errors of carbohydrate metabolism for a full list of inherited diseases that affect glycogen synthesis, glycogen breakdown, or glucose breakdown.)

Types

Type
(Eponym) ! Enzyme deficiency
(Gene) 		Incidence (births) ! Hypo-
glycemia? 		Hepato-
megaly? ! Hyper-
lipidemia? 		Muscle symptoms ! Development/ prognosis Other symptoms - GSD 0(Lewis' disease)[4] Glycogen synthase
(Muscle GYS1 / Liver GYS2) 		1 in 20,000–25,000[5] Liver 0a: YesMuscle 0b: No No No (Muscle 0b) Glycogen deficiency in muscle fibres. Type I muscle fibre predominance. Exercise-induced, muscle fatigue, myalgia, fainting.[6] [7] Occasional muscle cramping (Liver 0a) Growth failure in some cases.(Muscle 0b) Risk of sudden death in childhood due to cardiac arrest. (Liver 0a) Epilepsy[8]

(Muscle 0b) Rarely epilepsy, tonic-clonic seizures. Arrhythmia, long QT syndrome.

GSD I / GSD 1
(von Gierke's disease) 		Glucose-6-phosphatase / Glucose-6-phosphate translocase
(G6PC / SLC37A4 /SLC17A3) 		1 in 50,000 – 100,000[9] [10] Yes Yes Yes None - GSD II / GSD 2
(Pompe disease, formerly GSD-IIa)----Danon disease (formerly GSD-IIb) 		Acid alpha-glucosidase(GAA)----Lysosome-associated membrane protein 2
(LAMP2) 		Pompe disease is 1 in 13,000.[11] No Yes No Muscle weakness, exercise intolerance, abnormal lysosomal glycogen accumulation in muscle biopsy. Late-onset Pompe may have a pseudoathletic appearance of hypertrophic calf muscles.[12] The symptoms of both Pompe and Danon diseases are very similar due to a defect in lysosomes. However, in Danon disease, some show abnormal glycogen accumulation, but not all.[13] Progressive proximal skeletal muscle weakness with varied timeline to threshold of functional limitation (early childhood to adulthood). Approximately 15% of the Pompe population is classified as infantile Pompe which is typically deadly within the first year if untreated. Heart failure (infantile), respiratory difficulty (due to muscle weakness) - GSD III / GSD 3
(Cori's disease or Forbes' disease) 		Glycogen debranching enzyme
(AGL) 		1 in 100,000 Yes Yes Yes Myopathy. May have a pseudoathletic appearance of hypertrophic muscles. Failure to thrive[14] myogenic hyperuricemia[15]
GSD IV / GSD 4
(Andersen's disease) 		Glycogen branching enzyme
(GBE1) 		1 in 500,000[16] No No Myopathy and dilated cardiomyopathy Failure to thrive, death at age ~5 years - GSD V / GSD 5
(McArdle's disease) 		Muscle glycogen phosphorylase
(PYGM) 		1 in 100,000 – 500,000[17] No No No Exercise-induced muscle fatigue and cramps. Rhabdomyolysis possible. May have a pseudoathletic appearance of hypertrophic calf muscles.[18] - GSD VI / GSD 6
(Hers' disease) 		Liver glycogen phosphorylase
(PYGL) 		1 in 65,000 – 85,000[19] Yes Yes Yes[20] None initially benign, developmental delay follows. - GSD VII / GSD 7
(Tarui's disease) 		Muscle phosphofructokinase
(PFKM) 		1 in 1,000,000[21] No No No Exercise-induced muscle cramps and weakness - GSD IX / GSD 9 Phosphorylase kinase
(PHKA2 / PHKB / PHKG2 / PHKA1) 		? Yes Yes Yes IXd Exercise-induced muscle cramps, stiffness, weakness (fatigue), and pain.[22] - GSD X / GSD 10 Muscle Phosphoglycerate mutase(PGAM2)? ? ? ? Exercise-induced muscle cramps and weakness Myoglobinuria[23] - GSD XI / GSD 11 Muscle lactate dehydrogenase
(LDHA) 		? ? ? ? Exercise-induced muscle cramps, stiffness, pain.[24] - Fanconi-Bickel syndrome
formerly GSD XI / GSD 11, no longer considered a GSD 		Glucose transporter
(GLUT2) 		? Yes Yes No None - GSD XII / GSD 12
Aldolase A
(ALDOA) 		? No In some No Exercise intolerance, cramps. In some Rhabdomyolysis. - GSD XIII / GSD 13 β-enolase
(ENO3) 		? No ? No Increasing intensity of myalgias over decades[25] Serum CK

Episodic elevations; Reduced with rest

CDG1T (formally GSD XIV / GSD 14)Phosphoglucomutase-1(PGM1)?Episodic?NoTwo forms: exclusively myopathic and multi-system (including muscles).[26] Myopathy (including exercise-related fatigue, exercise intolerance, muscle weakness).Muscle biopsy shows glycogen accumulation.[27] Short stature, some have developmental delay, and rarely delayed puberty.Highly variable phenotype and severity. Commonly elevated serum CK, abnormal serum transferrin (loss of complete N-glycans), short stature, cleft palate, bifid uvula, and hepatopathy.Second Wind phenomenon in some[28] but not all
GSD XV / GSD 15 Glycogenin-1
(GYG1) 		Rare[29] No No No Muscle atrophy, exercise intolerance, muscle biopsy shows abnormal glycogen depletion and marked proliferation of slow-twitch (type 1/oxidative) muscle fibres and mitochondrial proliferation. Slowly progressive weakness over decades Arrhythmia, biopsy of heart showed abnormal glycogen deposits (different from polyglucosan bodies) in cardiomyocytes.[30]

Remarks:

Diagnosis

Methods to diagnose glycogen storage diseases include history and physical examination for associated symptoms, blood tests for associated metabolic disturbances, and genetic testing for suspected mutations.[41] It may also include a non-ischemic forearm test, exercise stress test, or 12-minute walk test (12MWT).[42] Advancements in genetic testing are slowly diminishing the need for biopsy; however, in the event of a VUS and inconclusive exercise tests, a biopsy would then be necessary to confirm diagnosis.

Differential diagnosis

Muscle

Glycogen storage diseases that involve skeletal muscle typically have exercise-induced (dynamic) symptoms, such as premature muscle fatigue, rather than fixed weakness (static) symptoms.[43] Differential diagnoses for glycogen storage diseases that involve fixed muscle weakness, particularly of the proximal muscles, would be an inflammatory myopathy or a limb-girdle muscular dystrophy.

For those with exercise intolerance and/or proximal muscle weakness, the endocrinopathies should be considered.[44] [45] The timing of the symptoms of exercise intolerance, such as muscle fatigue and cramping, is important in order to help distinguish it from other metabolic myopathies such as fatty acid metabolism disorders.[46]

Problems originating within the circulatory system, rather than the muscle itself, can produce exercise-induced muscle fatigue, pain and cramping that alleviates with rest, resulting from inadequate blood flow (ischemia) to the muscles. Ischemia that often produces symptoms in the leg muscles includes intermittent claudication, popliteal artery entrapment syndrome, and chronic venous insufficiency.

Diseases disrupting the neuromuscular junction can cause abnormal muscle fatigue, such as myasthenia gravis, an autoimmune disease.[47] Similar, are Lambert–Eaton myasthenic syndrome (autoimmune) and the congenital myasthenic syndromes (genetic).

Diseases can disrupt glycogen metabolism secondary to the primary disease. Abnormal thyroid function—hypo- and hyperthyroidism—can manifest as myopathy with symptoms of exercise-induced muscle fatigue, cramping, muscle pain and may include proximal weakness or muscle hypertrophy (particularly of the calves).[48] Hypothyroidism up-regulates glycogen synthesis and down-regulates glycogenolysis and glycolysis; conversely, hyperthyroidism does the reverse, up-regulating glycogenolysis and glycolysis while down-regulating glycogen synthesis.[49] [50] [51]

Prolonged hypo- and hyperthyroid myopathy leads to atrophy of type II (fast-twitch/glycolytic) muscle fibres, and a predominance of type I (slow-twitch/oxidative) muscle fibres. Muscle biopsy shows abnormal muscle glycogen: high accumulation in hypothyroidism and low accumulation in hyperthyroidism. Hypothyroid myopathy includes Kocher-Debre-Semelaigne syndrome (childhood-onset), Hoffman syndrome (adult-onset), myasthenic syndrome, and atrophic form.

In patients with increased growth hormone, muscle biopsy includes, among other features, excess glycogen deposition.

It is interesting to note, in comparison to hypothyroid myopathy, that McArdle disease (GSD-V), which is by far the most commonly diagnosed of the muscle GSDs and therefore the most studied, has as its second highest comorbidity endocrine disease (chiefly hypothyroidism)[52] and that some patients with McArdle disease also have hypertrophy of the calf muscles. Late-onset Pompe disease (GSD-II) also has calf hypertrophy and hypothyroidism as comorbidities.[53] [54]

Poor diet and malabsorption diseases (such as celiac disease) may lead to malnutrition of essential vitamins necessary for glycogen metabolism within the muscle cells. Malnutrition typically presents with systemic symptoms, but in rare instances can be limited to myopathy.[55] Vitamin D deficiency myopathy (also known as osteomalic myopathy due to the interplay between vitamin D and calcium) results in muscle weakness, predominantly of the proximal muscles; with muscle biopsy showing abnormal glycogen accumulation, atrophy of type II (fast-twitch/glycolytic) muscle fibres, and diminished calcium uptake by the sarcoplasmic reticulum (needed for muscle contraction).[56] [57] [58] Although Vitamin D deficiency myopathy typically includes muscle atrophy, rarely calf muscle hypertrophy has been reported.[59] [60]

Exercise-induced, electrically silent, muscle cramping and stiffness (transient muscle contractures or "pseudomyotonia") are seen not only in GSD types V, VII, IXd, X, XI, XII, and XIII, but also in Brody disease, Rippling muscle disease types 1 and 2, and CAV3-related hyperCKemia (Elevated serum creatine phosphokinase).[61] Unlike the other myopathies, in Brody disease the muscle cramping is painless.[62] [63] Like GSD types II, III, and V, a pseudoathletic appearance of muscle hypertrophy is also seen in some with Brody disease and Rippling muscle disease.[64] [65]

Erythrocyte lactate transporter defect (formerly Lactate transporter defect, myopathy due to) also includes exercise-induced, electrically silent, painful muscle cramping and transient contractures; as well as exercise-induced muscle fatigue.[66] EMG and muscle biopsy is normal however, as the defect is not in the muscle but in the red blood cells that should clear lactate buildup from exercising muscles.

Although most muscular dystrophies have fixed muscle weakness rather than exercise-induced muscle fatigue and/or cramping, there are a few exceptions. Limb–girdle muscular dystrophy autosomal recessive 23 (LGMD R23) has calf hypertrophy and exercise-induced cramping.[67] Myofibrillar myopathy 10 (MFM10) has exercise-induced muscle fatigue, cramping and stiffness, with hypertrophic neck and shoulder girdle muscles.[68] LGMD R28 has calf hypertrophy and exercise-induced muscle fatigue and pain.[69] LGMD R8 has calf pseudohypertrophy and exercise-induced weakness (fatigue) and pain.[70] LGMD R15 (a.k.a MDDGC3) has muscle hypertrophy, proximal muscle weakness, and muscle fatigue.[71]

DMD-related myopathies of Duchenne and Becker muscular dystrophy are known for fixed muscle weakness and pseudohypertrophic calf muscles, but they also have secondary muscular mitochondrial impairment causing low ATP production; as well as decreasing type II (fast-twitch/glycolytic) muscle fibres, producing a predominance of type I (slow-twitch/oxidative) muscle fibres.[72] DMD-related childhood-onset milder phenotypes present with exercise-induced muscle cramping, stiffness, pain, fatigue, and elevated CK.[73] Becker muscular dystrophy has adult-onset exercise-induced muscle cramping, pain, and elevated CK.[74]

Tubular aggregate myopathy (TAM) types 1 and 2 has exercise-induced muscle pain, fatigue, stiffness, with proximal muscle weakness and calf muscle pseudohypertrophy. TAM1 has cramping at rest, while TAM2 has cramping during exercise.[75] [76] [77] [78] Stormorken syndrome includes the symptoms of TAM, but is a more severe presentation including short stature and other abnormalities. Satoyoshi syndrome has exercise-induced painful muscle cramps, muscle hypertrophy, and short stature.[79] Dimethylglycine dehydrogenase deficiency has muscle fatigue, elevated CK, and fishy body odour.[80] Myopathy with myalgia, increased serum creatine kinase, with or without episodic rhabdomyolysis (MMCKR) has exercise-induced muscle cramps, pain, and fatigue; with some exhibiting proximal muscle weakness.[81]

Liver

(help wikipedia by contributing to this subsection)

Glycogenosis-like phenotype of congenital hyperinsulinism due to HNF4A mutation or MODY1 (maturity-onset diabetes of the young, type 1). This phenotype of MODY1 has macrosomia and infantile-onset hyperinsulinemic hypoglycemia, physiological 3-OH butyrate, increased triglyceride serum levels, increased level of glycogen in liver and erythrocytes, increased liver transaminases, transient hepatomegaly, renal Fanconi syndrome, and later develop liver cirrhosis, decreased succinate-dependent respiration (mitochondrial dysfunction), rickets, nephrocalcinosis, chronic kidney disease, and diabetes.[82] [83] [84]

Treatment

Treatment is dependent on the type of glycogen storage disease. Von Gierke disease (GSD-I) is typically treated with frequent small meals of carbohydrates and cornstarch, called modified cornstarch therapy, to prevent low blood sugar, while other treatments may include allopurinol and human granulocyte colony stimulating factor.[85]

Cori/Forbes disease (GSD-III) treatment may use modified cornstarch therapy, a high protein diet with a preference to complex carbohydrates. However, unlike GSD-I, gluconeogenesis is functional, so simple sugars (sucrose, fructose, and lactose) are not prohibited.

A ketogenic diet has demonstrated beneficial for McArdle disease (GSD-V) as ketones readily convert to acetyl CoA for oxidative phosphorylation, whereas free fatty acids take a few minutes to convert into acetyl CoA.[86] [87]

For phosphoglucomutase deficiency (formerly GSD-XIV), D-galactose supplements and exercise training has shown favourable improvement of signs and symptoms. In terms of exercise training, some patients with phosphoglucomutase deficiency also experience "second wind."

For McArdle disease (GSD-V), regular aerobic exercise utilizing "second wind" to enable the muscles to become aerobically conditioned, as well as anaerobic exercise (strength training) that follows the activity adaptations so as not to cause muscle injury, helps to improve exercise intolerance symptoms and maintain overall health.[88] [89] [90] Studies have shown that regular low-moderate aerobic exercise increases peak power output, increases peak oxygen uptake (V̇O2peak), lowers heart rate, and lowers serum CK in individuals with McArdle disease.

Regardless of whether the patient experiences symptoms of muscle pain, muscle fatigue, or cramping, the phenomenon of second wind having been achieved is demonstrable by the sign of an increased heart rate dropping while maintaining the same speed on the treadmill. Inactive patients experienced second wind, demonstrated through relief of typical symptoms and the sign of an increased heart rate dropping, while performing low-moderate aerobic exercise (walking or brisk walking).

Conversely, patients that were regularly active did not experience the typical symptoms during low-moderate aerobic exercise (walking or brisk walking), but still demonstrated second wind by the sign of an increased heart rate dropping.[91] For the regularly active patients, it took more strenuous exercise (very brisk walking/jogging or bicycling) for them to experience both the typical symptoms and relief thereof, along with the sign of an increased heart rate dropping, demonstrating second wind.[92]

In young children (<10 years old) with McArdle disease (GSD-V), it may be more difficult to detect the second wind phenomenon. They may show a normal heart rate, with normal or above normal peak cardio-respiratory capacity (V̇O2max).[93] That said, patients with McArdle disease typically experience symptoms of exercise intolerance before the age of 10 years, with the median symptomatic age of 3 years.[94] [95]

Tarui disease (GSD-VII) patients do not experience the "second wind" phenomenon; instead are said to be "out-of-wind." However, they can achieve sub-maximal benefit from lipid metabolism of free fatty acids during aerobic activity following a warm-up.

Epidemiology

Overall, according to a study in British Columbia, approximately 2.3 children per 100,000 births (1 in 43,000) have some form of glycogen storage disease.[96] In the United States, they are estimated to occur in 1 per 20,000–25,000 births.[97] Dutch incidence rate is estimated to be 1 per 40,000 births.While a Mexican incidence showed 6.78:1000 male newborns.[98]

Within the category of muscle glycogenoses (muscle GSDs), McArdle disease (GSD-V) is by far the most commonly diagnosed.

See also

External links

Notes and References

  1. 10.3233/NPM-1831. 30741698. Glucose-6-Phosphate dehydrogenase deficiency incidence in a Hispanic population. Journal of Neonatal-Perinatal Medicine. 203–207. 2019. Cantú-Reyna. C.. Santos-Guzmán. J.. Cruz-Camino. H.. Vazquez Cantu. D.L.. Góngora-Cortéz. J.J.. Gutiérrez-Castillo. A.. 12. 2. 73452760.
  2. Stegelmeier BL, Molyneux RJ, Elbein AD, James LF. May 1995. The lesions of locoweed (Astragalus mollissimus), swainsonine, and castanospermine in rats. Veterinary Pathology. 32. 3. 289–98. 10.1177/030098589503200311. 7604496. 45016726. free.
  3. Stojkovic . Tanya . Vissing . John . Petit . François . Piraud . Monique . Orngreen . Mette C. . Andersen . Grete . Claeys . Kristl G. . Wary . Claire . Hogrel . Jean-Yves . Laforêt . Pascal . 2009-07-23 . Muscle Glycogenosis Due to Phosphoglucomutase 1 Deficiency . New England Journal of Medicine . en . 361 . 4 . 425–427 . 10.1056/NEJMc0901158 . 19625727 . 0028-4793. free .
  4. Web site: Glycogen Storage Diseases . 2023-12-29 . Cleveland Clinic . en.
  5. 2022-10-10 . Glycogen-Storage Disease Type 0 (GSD-0) (Glycogen Synthetase Deficiency): Background, Pathophysiology, Epidemiology .
  6. Web site: GLYCOGEN STORAGE DISEASE 0, MUSCLE; GSD0B . 2023-12-29 . www.omim.org . en-us.
  7. Web site: Glycogen Storage Disease type 0 . MedLine Plus.
  8. Web site: GLYCOGEN STORAGE DISEASE 0, LIVER; GSD0A . 2023-12-29 . www.omim.org . en-us.
  9. Web site: Glycogen Storage Disease Type I. Association for Glycogen Storage Diseases (AGSD). October 2006. https://web.archive.org/web/20210411204929/https://agsdus.org/type-i.php. 11 April 2021.
  10. Cantú-Reyna . C.. Santos-Guzmán. J.. Cruz-Camino . H.. .Vazquez Cantu . D.L.. Góngora-Cortéz . J.J. . Gutiérrez-Castillo . A.. Glucose-6-Phosphate dehydrogenase deficiency incidence in a Hispanic population . Journal of Neonatal-Perinatal Medicine . 4 February 2019. 12 . 2. 203–207. 10.3233/NPM-1831. 30741698 . 73452760.
  11. Newborn Screening for Pompe Disease. 10.1542/peds.2016-0280C. 2017. Bodamer. Olaf A.. Scott. C. Ronald. Giugliani. Roberto. Pompe Disease Newborn Screening Working Group. Pediatrics. 140. Suppl 1. S4–S13. 29162673. 43782810. free.
  12. Menon . M. Suraj . Roopch . P. Sreedharan . Kabeer . K. Abdulkhayar . Shaji . C. Velayudhan . July 2016 . Calf Muscle Hypertrophy in Late Onset Pompe's Disease . Archives of Medicine and Health Sciences . en-US . 4 . 2 . 251 . 10.4103/2321-4848.196188 . 2321-4848 . 58424073 . free.
  13. Web site: 3 June 1986 . OMIM - # 300257 DANON DISEASE . OMIM — Online Medelian Inheritance in Man.
  14. Web site: Tegay . David H . Genetics of Glycogen-Storage Disease Type III Clinical Presentation: History, Physical, Causes . Medscape Reference . March 15, 2022 . October 24, 2023.
  15. Mineo I, Kono N, Hara N, Shimizu T, Yamada Y, Kawachi M, Kiyokawa H, Wang YL, Tarui S. Myogenic hyperuricemia. A common pathophysiologic feature of glycogenosis types III, V, and VII. N Engl J Med. 1987 Jul 9;317(2):75-80. doi: 10.1056/NEJM198707093170203. PMID 3473284.
  16. 10.1093/bjaceaccp/mkq055. Perioperative care of children with inherited metabolic disorders. Continuing Education in Anaesthesia, Critical Care & Pain. 11. 2. 62–68. 2011. Stuart. Grant. Ahmad. Nargis. free.
  17. Book: Khattak. Zoia E.. McArdle Disease. January 2022. StatPearls. Treasure Island, Florida (FL). live. https://web.archive.org/web/20220427180218/http://www.ncbi.nlm.nih.gov/books/NBK560785/. 27 April 2022. StatPearls Publishing. 32809620. 7 July 2022. Ashraf. Muddasir.
  18. Rodríguez-Gómez . I. . Santalla . A. . Díez-Bermejo . J. . Munguía-Izquierdo . D. . Alegre . L. M. . Nogales-Gadea . G. . Arenas . J. . Martín . M. A. . Lucía . A. . Ara . I. . November 2018 . Non-osteogenic muscle hypertrophy in children with McArdle disease . Journal of Inherited Metabolic Disease . 41 . 6 . 1037–1042 . 10.1007/s10545-018-0170-7 . 1573-2665 . 29594644. 10578/19657 . 4394513 . free .
  19. News: Genetics of Glycogen Storage Disease Type VI (Hers Disease). eMedicine (Medscape Reference). Anna V.. Blenda. Renee J.. Chosed. Mary L.. Windle. Lynne I. Curto. Maria. Descartes. Edward. Kaye. 4 Aug 2008. https://web.archive.org/web/20220101134503/https://emedicine.medscape.com/article/950587-overview. 1 January 2022.
  20. Book: Goldman. Lee. Schafer. Andrew. Goldman's Cecil medicine. 2012. 24th. Elsevier/Saunders. Philadelphia. 978-1-4377-1604-7. 1356.
  21. Web site: Rare Disease Database. Orpha.net. 2015-09-20.
  22. Web site: GLYCOGEN STORAGE DISEASE IXd; GSD9D . 2023-12-29 . www.omim.org . en-us.
  23. Web site: Phosphoglycerate mutase deficiency. Reference. Genetics Home. Genetics Home Reference. en. 2019-02-06.
  24. Web site: GLYCOGEN STORAGE DISEASE XI; GSD11 . 2023-12-29 . www.omim.org . en-us.
  25. Web site: Glycogenoses.
  26. Altassan . Ruqaiah . Radenkovic . Silvia . Edmondson . Andrew C. . Barone . Rita . Brasil . Sandra . Cechova . Anna . Coman . David . Donoghue . Sarah . Falkenstein . Kristina . Ferreira . Vanessa . Ferreira . Carlos . Fiumara . Agata . Francisco . Rita . Freeze . Hudson . Grunewald . Stephanie . January 2021 . International consensus guidelines for phosphoglucomutase 1 deficiency (PGM1-CDG): Diagnosis, follow-up, and management . Journal of Inherited Metabolic Disease . 44 . 1 . 148–163 . 10.1002/jimd.12286 . 0141-8955 . 7855268 . 32681750.
  27. Web site: Entry - #614921 - CONGENITAL DISORDER OF GLYCOSYLATION, TYPE It; CDG1T — OMIM . 2023-02-23 . omim.org . en-us.
  28. Preisler . Nicolai . Cohen . Jonathan . Vissing . Christoffer Rasmus . Madsen . Karen Lindhardt . Heinicke . Katja . Sharp . Lydia Jane . Phillips . Lauren . Romain . Nadine . Park . Sun Young . Newby . Marta . Wyrick . Phil . Mancias . Pedro . Galbo . Henrik . Vissing . John . Haller . Ronald Gerald . November 2017 . Impaired glycogen breakdown and synthesis in phosphoglucomutase 1 deficiency . Molecular Genetics and Metabolism . en . 122 . 3 . 117–121 . 10.1016/j.ymgme.2017.08.007. 28882528 .
  29. Malfatti E, Nilsson J, Hedberg-Oldfors C, Hernandez-Lain A, Michel F, Dominguez-Gonzalez C, Viennet G, Akman HO, Kornblum C, Van den Bergh P, Romero NB, Engel AG, DiMauro S, Oldfors A (2014) A new muscle glycogen storage disease associated with glycogenin-1 deficiency. Ann Neurol 76(6):891-898
  30. Moslemi . Ali-Reza . Lindberg . Christopher . Nilsson . Johanna . Tajsharghi . Homa . Andersson . Bert . Oldfors . Anders . April 2010 . Glycogenin-1 Deficiency and Inactivated Priming of Glycogen Synthesis . New England Journal of Medicine . en . 362 . 13 . 1203–1210 . 10.1056/NEJMoa0900661 . 20357282 . 0028-4793. free .
  31. Ludwig M, Wolfson S, Rennert O . Glycogen storage disease, type 8 . Arch. Dis. Child. . 47 . 255 . 830–833 . October 1972 . 4508182 . 1648209 . 10.1136/adc.47.255.830.
  32. https://www.omim.org/entry/306000 GLYCOGEN STORAGE DISEASE IXa1; GSD9A1
  33. Web site: Definition: glycogen storage disease type VIII from Online Medical Dictionary . 2008-09-01 . 2009-07-03 . https://web.archive.org/web/20090703034525/http://cancerweb.ncl.ac.uk/cgi-bin/omd?glycogen+storage+disease+type+VIII . dead .
  34. Web site: Glycogen Metabolism. Themedicalbiochemistrypage.org. 29 April 2020. 5 July 2022.
  35. Tegtmeyer . Laura C. . Rust . Stephan . van Scherpenzeel . Monique . Ng . Bobby G. . Losfeld . Marie-Estelle . Timal . Sharita . Raymond . Kimiyo . He . Ping . Ichikawa . Mie . Veltman . Joris . Huijben . Karin . Shin . Yoon S. . Sharma . Vandana . Adamowicz . Maciej . Lammens . Martin . 2014-02-06 . Multiple Phenotypes in Phosphoglucomutase 1 Deficiency . New England Journal of Medicine . en . 370 . 6 . 533–542 . 10.1056/NEJMoa1206605 . 0028-4793 . 4373661 . 24499211.
  36. Ortolano S, Vieitez I et al. Loss of cortical neurons underlies the neuropathology of Lafora disease. Mol Brain 2014;7:7
  37. Hedberg-Oldfors C, Oldfors A. Polyglucosan storage myopathies. Mol Aspects Med. 2015 Dec;46:85-100. doi: 10.1016/j.mam.2015.08.006. Epub 2015 Aug 13. PMID 26278982.
  38. Echaniz-Laguna A, Lornage X, Laforêt P, Orngreen MC, Edelweiss E, Brochier G, Bui MT, Silva-Rojas R, Birck C, Lannes B, Romero NB, Vissing J, Laporte J, Böhm J. A New Glycogen Storage Disease Caused by a Dominant PYGM Mutation. Ann Neurol. 2020 Aug;88(2):274-282. doi: 10.1002/ana.25771. Epub 2020 Jun 3. PMID 32386344.
  39. Echaniz-Laguna . A. . Lornage . X. . Edelweiss . E. . Laforêt . P. . Eymard . B. . Vissing . J. . Laporte . J. . Böhm . J. . October 2019 . O.5A new glycogen storage disorder caused by a dominant mutation in the glycogen myophosphorylase gene (PYGM) . Neuromuscular Disorders . en . 29 . S39 . 10.1016/j.nmd.2019.06.023. 203582211 .
  40. Rose MR, Howard RS, Genet SA, McMahon CJ, Whitfield A, Morgan-Hughes JA. A case of myopathy associated with a dystrophin gene deletion and abnormal glycogen storage. Muscle Nerve. 1993 Jan;16(1):57-62. doi: 10.1002/mus.880160110. PMID 8423832.
  41. Kishnani . Priya S. . Austin . Stephanie L. . Arn . Pamela . Bali . Deeksha S. . Boney . Anne . Case . Laura E. . Chung . Wendy K. . Desai . Dev M. . El-Gharbawy . Areeg . Haller . Ronald . Smit . G. Peter A. . Smith . Alastair D. . Hobson-Webb . Lisa D. . Wechsler . Stephanie Burns . Weinstein . David A. . July 2010 . Glycogen Storage Disease Type III diagnosis and management guidelines . Genetics in Medicine . en . 12 . 7 . 446–463 . 10.1097/GIM.0b013e3181e655b6 . 20631546 . 4609175 . 1530-0366. free .
  42. Lucia . Alejandro . Martinuzzi . Andrea . Nogales-Gadea . Gisela . Quinlivan . Ros . Reason . Stacey . International Association for Muscle Glycogen Storage Disease study group . December 2021 . Clinical practice guidelines for glycogen storage disease V & VII (McArdle disease and Tarui disease) from an international study group . Neuromuscular Disorders . 31 . 12 . 1296–1310 . 10.1016/j.nmd.2021.10.006 . 1873-2364 . 34848128. 240123241 . free .
  43. Darras . B. T. . Friedman . N. R. . February 2000 . Metabolic myopathies: a clinical approach; part I . Pediatric Neurology . 22 . 2 . 87–97 . 10.1016/s0887-8994(99)00133-2 . 0887-8994 . 10738913.
  44. Rodolico . Carmelo . Bonanno . Carmen . Pugliese . Alessia . Nicocia . Giulia . Benvenga . Salvatore . Toscano . Antonio . 2020-09-01 . Endocrine myopathies: clinical and histopathological features of the major forms . Acta Myologica . 39 . 3 . 130–135 . 10.36185/2532-1900-017 . 1128-2460 . 7711326 . 33305169.
  45. Sharma . Vikas . Borah . Papori . Basumatary . Lakshya J. . Das . Marami . Goswami . Munindra . Kayal . Ashok K. . 2014 . Myopathies of endocrine disorders: A prospective clinical and biochemical study . Annals of Indian Academy of Neurology . 17 . 3 . 298–302 . 10.4103/0972-2327.138505 . 0972-2327 . 4162016 . 25221399 . free.
  46. Web site: Bhai . Salman . September 2021 . Neuromuscular Notes: Diagnosing Metabolic Myopathies . May 24, 2023 . Practical Neurology . en.
  47. Gilhus . Nils Erik . 2021-03-01 . Physical training and exercise in myasthenia gravis . Neuromuscular Disorders . 31 . 3 . 169–173 . 10.1016/j.nmd.2020.12.004 . 229372884 . 0960-8966. 11250/2767222 . free .
  48. Web site: Myopathies associated with thyroid disease . 2023-05-24 . MedLink Neurology . en.
  49. Dimitriadis . G D . Leighton . B . Parry-Billings . M . West . D . Newsholme . E A . 1989-01-15 . Effects of hypothyroidism on the sensitivity of glycolysis and glycogen synthesis to insulin in the soleus muscle of the rat. . Biochemical Journal . 257 . 2 . 369–373 . 10.1042/bj2570369 . 0264-6021 . 1135589 . 2649073.
  50. Celsing . F. . Blomstrand . E. . Melichna . J. . Terrados . N. . Clausen . N. . Lins . P. E. . Jansson . E. . April 1986 . Effect of hyperthyroidism on fibre-type composition, fibre area, glycogen content and enzyme activity in human skeletal muscle . Clinical Physiology . 6 . 2 . 171–181 . 10.1111/j.1475-097x.1986.tb00066.x . 0144-5979 . 2937605.
  51. Brenta . Gabriela . 2011-09-19 . Why Can Insulin Resistance Be a Natural Consequence of Thyroid Dysfunction? . Journal of Thyroid Research . en . 2011 . e152850 . 10.4061/2011/152850 . 2090-8067 . 3175696 . 21941681 . free.
  52. Scalco . Renata S. . Lucia . Alejandro . Santalla . Alfredo . Martinuzzi . Andrea . Vavla . Marinela . Reni . Gianluigi . Toscano . Antonio . Musumeci . Olimpia . Voermans . Nicol C. . Kouwenberg . Carlyn V. . Laforêt . Pascal . San-Millán . Beatriz . Vieitez . Irene . Siciliano . Gabriele . Kühnle . Enrico . 2020-11-24 . Data from the European registry for patients with McArdle disease and other muscle glycogenoses (EUROMAC) . Orphanet Journal of Rare Diseases . 15 . 1 . 330 . 10.1186/s13023-020-01562-x . 1750-1172 . 7687836 . 33234167 . free.
  53. Schneider . Joseph . Burmeister . Lynn A. . Rudser . Kyle . Whitley . Chester B. . Jarnes Utz . Jeanine . September 2016 . Hypothyroidism in late-onset Pompe disease . Molecular Genetics and Metabolism Reports . 8 . 24–27 . 10.1016/j.ymgmr.2016.06.002 . 2214-4269 . 4932620 . 27408821.
  54. Fatehi . Farzad . Ashrafi . Mahmoud Reza . Babaee . Marzieh . Ansari . Behnaz . Beiraghi Toosi . Mehran . Boostani . Reza . Eshraghi . Peyman . Fakharian . Atefeh . Hadipour . Zahra . Haghi Ashtiani . Bahram . Moravej . Hossein . Nilipour . Yalda . Sarraf . Payam . Sayadpour Zanjani . Keyhan . Nafissi . Shahriar . 2021 . Recommendations for Infantile-Onset and Late-Onset Pompe Disease: An Iranian Consensus . Frontiers in Neurology . 12 . 739931 . 10.3389/fneur.2021.739931 . 1664-2295 . 8490649 . 34621239 . free.
  55. Rasheed . Khalid . Sethi . Pooja . Bixby . Eric . May 2013 . Severe vitamin d deficiency induced myopathy associated with rhabydomyolysis . North American Journal of Medical Sciences . 5 . 5 . 334–336 . 10.4103/1947-2714.112491 . 2250-1541 . 3690793 . 23814767 . free.
  56. Polly . Patsie . Tan . Timothy C. . 2014 . The role of vitamin D in skeletal and cardiac muscle function . Frontiers in Physiology . 5 . 145 . 10.3389/fphys.2014.00145 . 1664-042X . 3995052 . 24782788 . free.
  57. Yoshikawa . S. . Nakamura . T. . Tanabe . H. . Imamura . T. . June 1979 . Osteomalacic myopathy . Endocrinologia Japonica . 26 . Suppl . 65–72 . 10.1507/endocrj1954.26.supplement_65 . 0013-7219 . 467350 . free.
  58. Das . Anamica . Gopinath . Suchitra D. . Arimbasseri . Gopalakrishnan Aneeshkumar . February 2022 . Systemic ablation of vitamin D receptor leads to skeletal muscle glycogen storage disorder in mice . Journal of Cachexia, Sarcopenia and Muscle . 13 . 1 . 467–480 . 10.1002/jcsm.12841 . 2190-6009 . 8818613 . 34877816.
  59. Hassan . Ijas . Bhanudeep . Singanamalla . Madaan . Priyanka . Chhajed . Monika . Saini . Lokesh . 2021 . Bilateral Calf Hypertrophy and Isolated Motor Delay: Think Beyond Muscular Dystrophy . Journal of Pediatric Neurosciences . 16 . 2 . 173–174 . 10.4103/jpn.JPN_171_20 . 1817-1745 . 8706592 . 35018192 . free.
  60. Reimers . C. D. . Schlotter . B. . Eicke . B. M. . Witt . T. N. . November 1996 . Calf enlargement in neuromuscular diseases: a quantitative ultrasound study in 350 patients and review of the literature . Journal of the Neurological Sciences . 143 . 1–2 . 46–56 . 10.1016/s0022-510x(96)00037-8 . 0022-510X . 8981297 . 25971689.
  61. Web site: Exercise-induced muscle cramps (Concept Id: C1855578) - MedGen - NCBI . 2023-12-28 . www.ncbi.nlm.nih.gov . en.
  62. Web site: BRODY DISEASE; BROD . 2023-12-28 . www.omim.org . en-us.
  63. Molenaar . Joery P. . Verhoeven . Jamie I. . Rodenburg . Richard J. . Kamsteeg . Erik J. . Erasmus . Corrie E. . Vicart . Savine . Behin . Anthony . Bassez . Guillaume . Magot . Armelle . Péréon . Yann . Brandom . Barbara W. . Guglielmi . Valeria . Vattemi . Gaetano . Chevessier . Frédéric . Mathieu . Jean . 2020-02-01 . Clinical, morphological and genetic characterization of Brody disease: an international study of 40 patients . Brain: A Journal of Neurology . 143 . 2 . 452–466 . 10.1093/brain/awz410 . 1460-2156 . 7009512 . 32040565.
  64. Web site: RIPPLING MUSCLE DISEASE 1; RMD1 . 2023-12-28 . www.omim.org . en-us.
  65. Web site: RIPPLING MUSCLE DISEASE 2; RMD2 . 2023-12-28 . www.omim.org . en-us.
  66. Web site: ERYTHROCYTE LACTATE TRANSPORTER DEFECT . 2023-12-28 . www.omim.org . en-us.
  67. Web site: MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 23; LGMDR23 . 2023-12-28 . www.omim.org . en-us.
  68. Web site: MYOFIBRILLAR MYOPATHY 10; MFM10 . 2023-12-28 . www.omim.org . en-us.
  69. Web site: MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 28; LGMDR28 . 2023-12-28 . www.omim.org . en-us.
  70. Web site: MUSCULAR DYSTROPHY, LIMB-GIRDLE, AUTOSOMAL RECESSIVE 8; LGMDR8 . 2023-12-28 . www.omim.org . en-us.
  71. Web site: MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 3; MDDGC3 . 2023-12-28 . www.omim.org . en-us.
  72. Heydemann . Ahlke . 2018-06-20 . Skeletal Muscle Metabolism in Duchenne and Becker Muscular Dystrophy-Implications for Therapies . Nutrients . 10 . 6 . 796 . 10.3390/nu10060796 . free . 2072-6643 . 6024668 . 29925809.
  73. Veerapandiyan . Aravindhan . Shashi . Vandana . Jiang . Yong-Hui . Gallentine . William Brian . Schoch . Kelly . Smith . Edward Clinton . December 2010 . Pseudometabolic presentation of dystrophinopathy due to a missense mutation . Muscle & Nerve . 42 . 6 . 975–979 . 10.1002/mus.21823 . 1097-4598 . 5506871 . 21104870.
  74. Web site: MUSCULAR DYSTROPHY, BECKER TYPE; BMD . 2023-12-29 . www.omim.org . en-us.
  75. Web site: Tubular aggregate myopathy - About the Disease - Genetic and Rare Diseases Information Center . 2023-11-11 . rarediseases.info.nih.gov . en.
  76. Morin . Gilles . Biancalana . Valérie . Echaniz-Laguna . Andoni . Noury . Jean-Baptiste . Lornage . Xavière . Moggio . Maurizio . Ripolone . Michela . Violano . Raffaella . Marcorelles . Pascale . Maréchal . Denis . Renaud . Florence . Maurage . Claude-Alain . Tard . Céline . Cuisset . Jean-Marie . Laporte . Jocelyn . January 2020 . Tubular aggregate myopathy and Stormorken syndrome: Mutation spectrum and genotype/phenotype correlation . Human Mutation . 41 . 1 . 17–37 . 10.1002/humu.23899 . 1098-1004 . 31448844. free .
  77. Web site: MYOPATHY, TUBULAR AGGREGATE, 1; TAM1 . 2023-11-11 . www.omim.org . en-us.
  78. Web site: MYOPATHY, TUBULAR AGGREGATE, 2; TAM2 . 2023-11-11 . www.omim.org . en-us.
  79. Web site: SATOYOSHI SYNDROME . 2023-12-28 . www.omim.org . en-us.
  80. Web site: DIMETHYLGLYCINE DEHYDROGENASE DEFICIENCY; DMGDHD . 2023-12-28 . www.omim.org . en-us.
  81. Web site: MYOPATHY WITH MYALGIA, INCREASED SERUM CREATINE KINASE, AND WITH OR WITHOUT EPISODIC RHABDOMYOLYSIS; MMCKR . 2023-12-28 . www.omim.org . en-us.
  82. Grassi . Mara . Laubscher . Bernard . Pandey . Amit V. . Tschumi . Sibylle . Graber . Franziska . Schaller . André . Janner . Marco . Aeberli . Daniel . Hewer . Ekkehard . Nuoffer . Jean-Marc . Gautschi . Matthias . August 2023 . Expanding the p.(Arg85Trp) Variant-Specific Phenotype of HNF4A: Features of Glycogen Storage Disease, Liver Cirrhosis, Impaired Mitochondrial Function, and Glomerular Changes . Molecular Syndromology . 14 . 4 . 347–361 . 10.1159/000529306 . 1661-8769 . 37766831. 10521240 .
  83. Stanik . Juraj . Skopkova . Martina . Brennerova . Katarina . Danis . Daniel . Rosolankova . Monika . Salingova . Anna . Bzduch . Vladimir . Klimes . Iwar . Gasperikova . Daniela . April 2017 . Congenital hyperinsulinism and glycogenosis-like phenotype due to a novel HNF4A mutation . Diabetes Research and Clinical Practice . 126 . 144–150 . 10.1016/j.diabres.2017.02.014 . 1872-8227 . 28242437.
  84. Web site: Entry - #125850 - MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 1; MODY1 - OMIM . 2024-05-23 . www.omim.org.
  85. Web site: Glycogen Storage Disease Type I - NORD (National Organization for Rare Disorders). NORD (National Organization for Rare Disorders). 23 March 2017.
  86. Løkken . Nicoline . Hansen . Kit K. . Storgaard . Jesper H. . Ørngreen . Mette C. . Quinlivan . Ros . Vissing . John . July 2020 . Titrating a modified ketogenic diet for patients with McArdle disease: A pilot study . Journal of Inherited Metabolic Disease . en . 43 . 4 . 778–786 . 10.1002/jimd.12223 . 32060930 . 211121921 . 0141-8955.
  87. Løkken . Nicoline . Voermans . Nicol C. . Andersen . Linda K. . Karazi . Walaa . Reason . Stacey L. . Zweers . Heidi . Wilms . Gustav . Santalla . Alfredo . Susanibar . Edward . Lucia . Alejandro . Vissing . John . 2023-02-07 . Patient-Reported Experiences with a Low-Carbohydrate Ketogenic Diet: An International Survey in Patients with McArdle Disease . Nutrients . 15 . 4 . 843 . 10.3390/nu15040843 . 2072-6643 . 9964801 . 36839201 . free .
  88. Book: Wakelin, Andrew . Living With McArdle Disease . IamGSD (Internation Association for Muscle Glycogen Storage Disease) . 2017.
  89. Kitaoka . Yu . February 25, 2014 . McArdle Disease and Exercise Physiology . Biology . en . 3 . 1 . 157–166 . 10.3390/biology3010157 . 24833339 . 4009758 . 2079-7737 . free .
  90. Salazar-Martínez . Eduardo . Santalla . Alfredo . Valenzuela . Pedro L. . Nogales-Gadea . Gisela . Pinós . Tomàs . Morán . María . Santos-Lozano . Alejandro . Fiuza-Luces . Carmen . Lucia . Alejandro . 2021 . The Second Wind in McArdle Patients: Fitness Matters . Frontiers in Physiology . 12 . 744632 . 10.3389/fphys.2021.744632 . 1664-042X . 8555491 . 34721068 . free .
  91. Perez . M . Martin . M A . Rubio . J C . Maté-Muñoz . J L . Gómez-Gallego . F . Foster . C . Andreu . A L . Arenas . J . Lucia . A . August 2006 . Exercise capacity in a 78 year old patient with McArdle's disease: it is never too late to start exercising . British Journal of Sports Medicine . 40 . 8 . 725–726 . 10.1136/bjsm.2006.026666 . 0306-3674 . 2579473 . 16864568.
  92. Book: Wakelin, Andrew . 101Tips for a good life with McArdle Disease . AGSD-UK . 2013 . 52.
  93. Pérez . Margarita . Ruiz . Jonatan R. . Fernández del Valle . María . Nogales-Gadea . Gisela . Andreu . Antoni L. . Arenas . Joaquín . Lucía . Alejandro . 2009-06-01 . The second wind phenomenon in very young McArdle's patients . Neuromuscular Disorders . en . 19 . 6 . 403–405 . 10.1016/j.nmd.2009.04.010 . 19477644 . 31541581 . 0960-8966.
  94. Reason . S. L. . Voermans . N. . Lucia . A. . Vissing . J. . Quinlivan . R. . Bhai . S. . Wakelin . A. . 2023-06-12 . Development of Continuum of Care for McArdle disease: A practical tool for clinicians and patients . Neuromuscular Disorders . 33 . 7 . 575–579 . 10.1016/j.nmd.2023.05.006 . 1873-2364 . 37354872. 259141690 . free .
  95. Scalco . Renata Siciliani . Morrow . Jasper M. . Booth . Suzanne . Chatfield . Sherryl . Godfrey . Richard . Quinlivan . Ros . September 2017 . Misdiagnosis is an important factor for diagnostic delay in McArdle disease . Neuromuscular Disorders . 27 . 9 . 852–855 . 10.1016/j.nmd.2017.04.013 . 1873-2364 . 28629675. 11797963 . free .
  96. Applegarth DA, Toone JR, Lowry RB . Incidence of inborn errors of metabolism in British Columbia, 1969–1996 . Pediatrics . 105 . 1 . e10 . January 2000 . 10617747 . 10.1542/peds.105.1.e10. 30266513 .
  97. http://emedicine.medscape.com/article/949937-overview eMedicine Specialties > Glycogen-Storage Disease Type I
  98. Cantú-Reyna . Consuelo . Zepeda . Luis Manuel . Montemayor . René . Benavides . Santiago . González . Héctor Javier . Vázquez-Cantú . Mercedes . Cruz-Camino . Héctor . Incidence of Inborn Errors of Metabolism by Expanded Newborn Screening in a Mexican Hospital . Journal of Inborn Errors of Metabolism and Screening . 27 September 2016 . 4 . 232640981666902 . 10.1177/2326409816669027. free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Glycogen storage disease".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.